Biotechnology company Regeneron buying 23andMe for $256 million
23andMe has faced an uncertain future after struggles to find a profitable business model and privacy concerns related to customers’ genetic information.
23andMe has faced an uncertain future after struggles to find a profitable business model and privacy concerns related to customers’ genetic information.
What's Your Reaction?
